Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-10-30
2009-10-20
Hayes, Robert C (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000
Reexamination Certificate
active
07605127
ABSTRACT:
The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.
REFERENCES:
patent: 4959314 (1990-09-01), Mark et al.
patent: 4966963 (1990-10-01), Patroni
patent: 5004805 (1991-04-01), Gohda et al.
patent: 5316921 (1994-05-01), Godowski et al.
patent: 5328837 (1994-07-01), Godowski et al.
patent: 0 246 753 (1987-11-01), None
patent: WO 92/05184 (1992-04-01), None
patent: WO 93/23541 (1993-11-01), None
patent: WO 93/23550 (1993-11-01), None
patent: WO 94/06909 (1994-03-01), None
Rudinger, In “Peptide Hormones”, ed J.A. Parsons, University Park Press, Baltimore, pp. 1-7 (Jun. 1976).
Cunningham et al., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis.” Science 244(4908):1081-1085 (Jun. 1989).
N.A. Lokker et al., “Structure-Function Analysis of Hepatocyte Growth Factor: Identification of Variants That Lack Mitogenic Activity Yet Retain High Affinity . . .”,The EMBO Journal11(7): 2503-2510 (1992).
M. Okigaki et al., “Functional Characterization of Human Hepatocyte Growth Factor Mutants Obtained by Deletion of Structural Domains”,Biochemistry31: 9555-9561 (1992).
N.A. Lokker et al., “Generation and Characterization of a Competitive Antagonist of Human Hepatocyte Growth Factor, HGF/NK1”,The Journal of Biological Chemistry258(23): 17145-17150 (1993).
G. Hartmann et al., “A Functional Domain in the Heavy Chain of Scatter Factor/Hepatocyte Growth Factor Binds thec-MetReceptor and Induces . . .”,Proc. Natl. Acad. Sci. USA89: 11574-11578 (1992).
K. Miyazawa et al., “An Alternatively Processed mRNA Generated from Human Hepatocyte Growth Factor Gene”,Eur. J. Biochem. 197: 15-22 (1991).
T. Nakamura et al., “Molecular Cloning and Expression of Human Hepatocyte Growth Factor”,Nature342: 440-443 (1989).
K. Miyazawa et al., “Molecular Cloning and Sequence Analysis of cDNA for Human Hepatocyte Growth Factor”,Biochem. and Biophys. Res. Comm. 163(2): 967-973 (1989).
T. Seki et al., “Isolation and Expression of cDNA for Different Forms of Hepatocyte Growth Factor from Human Leukocyte”,Biochem. and Biophys. Res. Comm. 172(1): 321-327 (199O).
Finch et al., “Human KGF is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth”Science245: 752-755 (Aug. 1989).
Chan et al., “Isoforms of Human HGF and Their Biological Activities”,EXS, 65: 67-79 (1993).
Chan et al., “Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript,”Science, 254: 67-79 (Nov. 1991).
Datar et al., “Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator”Bio/Technology, 11: 349-355 (Mar. 1993).
Skerra et al., Assembly of A Functional Immunoglobulin FvFragment inEscherichia coli, Science, 240: 1038-1040 (May 1988).
Matsumoto et al., “Deletion of Kringe Domains or the N-Terminal Hairpin Structure in Hepatocyte Growth Factor Results in Marked Decreases in Related Biological Activities,”Biochemical and Biophysical Research Communications, 181(2): 691-699 (1991).
Gherardi et al., “Properties and Structure-Function Relationship of HGF-SF,” EXS, 65: 41-48 (1993).
Aaronson Stuart A.
Bottaro Donald P.
Chan Andrew M. L.
Cioce Vittoria
Rubin Jeffrey S.
Ballard Spahr Andrews & Ingersoll LLP
Hayes Robert C
The United States of America as represented by the Secretary of
LandOfFree
Truncated hepatocyte growth factor variant protein HGF/NK2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated hepatocyte growth factor variant protein HGF/NK2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated hepatocyte growth factor variant protein HGF/NK2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077008